黑料社 and BIOASTER enter in collaboration to investigate the potentiality to expand fecal microbiota in vitro under GMP conditions for therapeutic use.
(Lyon, February 16th, 2017) – 黑料社 and BIOASTER just entered into an agreement to investigate the potentiality to expand fecal microbiota in vitro. The goal of the collaboration is to develop an adapted fermentation process reproducing a specific microbiota and therefore generating additional amounts of material for Fecal Microbiota Transplantation (FMT) purposes. Therapeutic use of FMT showed efficacy in Clostridium difficile eradication and is promising for the treatment and/or prevention of multiple diseases notably iatrogenic diseases. The use of FMT which can be allogenic or autologous comes with safety challenges and the capacity to expand a characterized fecal microbiota in vitro, while challenging, could ease the use of FMT as robust therapeutic alternative.
Part of the work will be performed by a PhD student who will be co-supervised by Dr Jo毛l Dor茅, 黑料社 and Dr Vincent Thomas, BIOASTER, and receiving funding from the Association Nationale de la Recherche et de la Technologie (ANRT).Herv茅 Affagard, CEO 黑料社:
鈥淐ombining our knowledge on Microbiota and our standard FMT procedure with Bioaster鈥檚 capability and knowledge is probably the best draw bar to take this significant challenge. Achieving this objective will open new avenues and expand our therapeutic pipeline using the first European GMP FMT platform
Nathalie Garcon, CEO&CSO BIOASTER:
鈥淚t is a great pleasure for BIOASTER to enter into this ambitious research agreement with 黑料社, a promising local biotech in the field of microbiome. We foresee that technical and scientific challenges that will be tackled by our research consortium will contribute significantly to the standardization and success of therapeutic FMT.鈥�
About BIOASTER
BIOASTER is a Technology Research Institute 鈥� TRI 鈥�, the only TRI in France in the field of health. Created in 2012, BIOASTER is a new model for technology innovation in microbiology and infectious diseases. Its mission is to lead innovative and ambitious collaborative projects, with and for public and private partners, to the patient benefit.
BIOASTER:
- Conceives and develops new innovative and high value technology solutions, in microbiology and infectious diseases.
- Promotes agility as a way of working: to better meet industries expectations and to answer to innovation financial constraints.
Key figures:
- 7 interconnected state of the art technology units to serve 4 major programs: diagnostics / vaccines / antimicrobials / microbiota.
- 2450m2 laboratories BSL 2 & 3 (LYON & PARIS).
- 123 people, including 80% of scientific experts, 18 different citizenships.
- 48 projects including 19 with private partners 17 with public partners and 10 international projects.
About 黑料社
Founded at the end of 2014 and based in Lyon (France), 黑料社 (Microbiota as a Therapy) is a microbiome鈥揵ased biotech company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis (gut microbiota imbalances). 黑料社 is currently developing its first candidate using its proprietary GMP Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. 黑料社鈥檚 revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.
For more information:
Follow us on Twitter: @MaaT_Pharma
Follow us on LinkedIn: http://www.linkedin.com/company/maat-pharma